GOODRX HOLDINGS INC

Inside GoodRx’s latest insider trades, see how McGinnis’s round‑trip buying and selling could signal tactical moves amid Paytient partnership buzz.

GoodRx insider Hirsch Douglas Joseph buys 4,642 shares, boosting confidence in the company’s growth. Discover why this move signals optimism and potential upside for investors.

GoodRx insider trading reveals cautious optimism: Chief accounting officer Chan Thomas buys 1,300 shares amid volatile markets, signaling measured confidence in the digital‑health company’s growth strategy.

GoodRx insider buys signal growing confidence, rising social‑media buzz and a potential shift toward dynamic growth amid evolving prescription‑pricing dynamics.

GoodRx insider RSU buys signal long‑term confidence, but the company’s 50% YTD drop and low valuation demand cautious, data‑driven investment decisions.

GoodRx insider Nabiey Romin’s February 8 trades reveal a balanced buy‑sell strategy that keeps executives invested while managing cash, offering investors insight into the company’s confidence and liquidity play amid market volatility.